WuXi Biologics

WuXi Biologics, established in 2014, is a premier global provider of integrated technology platforms for biologics drug development. The company specializes in end-to-end solutions, ranging from discovery and research to commercial manufacturing. By leveraging its state-of-the-art technological platforms, WuXi Biologics supports clients through the entire drug development lifecycle, including antibody-drug conjugate development, biosafety testing, and GMP-grade plasmid DNA production. With annual revenue reaching $3.2B, the firm maintains a robust market position in the biotechnology sector.

Operating with a workforce of over 10,000 employees, the organization maintains a significant global footprint to facilitate complex bioprocess engineering and regulatory strategy execution. The company’s infrastructure includes high-efficiency manufacturing facilities designed to meet rigorous international quality standards. Meet WuXi Biologics's team to understand the organizational structure and the expert talent driving these complex scientific operations. The firm’s commitment to high-throughput screening and analytical services ensures that partners receive optimized, customizable development programs tailored to specific clinical requirements.

As a leader in the biotechnology sector, WuXi Biologics provides a single-source manufacturing partner model that streamlines the transition from clinical trials to commercial drug substance production. The company’s expertise spans multiple modalities, including next-generation antibody-drug conjugates and stable cell line engineering. By integrating advanced methodology with robust regulatory support, the firm enables clients to accelerate their drug development programs effectively. WuXi Biologics continues to expand its industry-leading expertise, maintaining a competitive edge through continuous investment in R&D capabilities and technological innovation across its global network.